自动CT分析预测特发性肺纤维化结局
本研究评估计算机衍生的CT定量指标(尤其是肺血管相关结构VRS评分)能否预测IPF患者的功能下降和生存,并减少药物试验所需样本量。在发现队列247例和验证队列284例符合试验入组标准的IPF患者中,CALIPER衍生的VRS评分是生存和FVC下降的最强预测因子之一,且在病变较轻患者中更突出。VRS评分>4.4%肺容积作为队列富集工具可将所需样本量减少26%,并识别抗纤维化药物延长生存和减缓FVC下降的患者。
要点
- CALIPER衍生的VRS评分是IPF患者生存和FVC下降的最强预测因子之一,优于肺功能指标。
- VRS评分>4.4%肺容积作为队列富集工具可将IPF药物试验所需样本量减少26%。
- VRS评分可识别抗纤维化药物延长生存和减缓FVC下降的IPF患者。
核心结论
- VRS评分是一种新的定量CT指标,在符合药物试验入组标准的IPF患者中优于当前金标准结局预测指标。
- VRS阈值评分用于队列富集可将所需IPF药物试验人群规模减少25%,从而限制试验成本。
- VRS评分可识别抗纤维化药物延长生存和减少FVC下降的患者。
研究设计与样本
- 研究在伦敦Royal Brompton医院和乌得勒支St. Antonius医院进行,纳入接受容积非增强CT成像的IPF患者。
- 发现队列为247例连续患者,验证队列为284例患者,均符合药物试验入组标准。
主要发现
- 在发现和验证队列中,CALIPER衍生特征(尤其是VRS评分)是生存和FVC下降的最强预测因子之一。
- CALIPER结果在病变范围较小的患者中更为突出,优于肺功能指标。
- CALIPER VRS评分>4.4%肺容积作为队列富集工具可将IPF药物试验所需样本量减少26%。
关键数值与推荐
- CALIPER VRS评分>4.4%肺容积作为队列富集阈值。
- 使用VRS阈值评分可将所需IPF药物试验人群规模减少25%。
临床怎么用
- 在IPF药物试验中,可采用CALIPER衍生的VRS评分进行队列富集,以减少所需样本量和试验成本。
- VRS评分有助于识别可能从抗纤维化药物治疗中获益(延长生存、减缓FVC下降)的IPF患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Quantitative computed tomographic (CT) measures of baseline disease severity might identify patients with idiopathic pulmonary fibrosis (IPF) with an increased mortality risk. We evaluated whether quantitative CT variables could act as a cohort enrichment tool in future IPF drug trials. OBJECTIVES: To determine whether computer-derived CT measures, specifically measures of pulmonary vessel-related structures (VRSs), can better predict functional decline and survival in IPF and reduce requisite sample sizes in drug trial populations. METHODS: Patients with IPF undergoing volumetric noncontrast CT imaging at the Royal Brompton Hospital, London, and St. Antonius Hospital, Utrecht, were examined to identify pulmonary function measures (including FVC) and visual and computer-derived (CALIPER [Computer-Aided Lung Informatics for Pathology Evaluation and Rating] software) CT features predictive of mortality and FVC decline. The discovery cohort comprised 247 consecutive patients, with validation of results conducted in a separate cohort of 284 patients, all fulfilling drug trial entry criteria. MEASUREMENTS AND MAIN RESULTS: In the discovery and validation cohorts, CALIPER-derived features, particularly VRS scores, were among the strongest predictors of survival and FVC decline. CALIPER results were accentuated in patients with less extensive disease, outperforming pulmonary function measures. When used as a cohort enrichment tool, a CALIPER VRS score greater than 4.4% of the lung was able to reduce the requisite sample size of an IPF drug trial by 26%. CONCLUSIONS: Our study has validated a new quantitative CT measure in patients with IPF fulfilling drug trial entry criteria-the VRS score-that outperformed current gold standard measures of outcome. When used for cohort enrichment in an IPF drug trial setting, VRS threshold scores can reduce a required IPF drug trial population size by 25%, thereby limiting prohibitive trial costs. Importantly, VRS scores identify patients in whom antifibrotic medication prolongs life and reduces FVC decline.
引用
- Jacob J, Bartholmai BJ, Rajagopalan S, et al. Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. Am J Respir Crit Care Med. 2018. PMID: 29684284. doi:10.1164/rccm.201711-2174OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。